Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2000 / Article

Open Access

Volume 14 |Article ID 405638 |

Jane D Collier, Paul A Adams, Victor Feinman, Cameron Ghent, Helga Witt-Sullivan, Gerald Minuk, Mel Krajden, Jenny Heathcote, "Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon", Canadian Journal of Gastroenterology and Hepatology, vol. 14, Article ID 405638, 5 pages, 2000.

Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon

Received25 Jan 2000
Accepted15 Feb 2000


Interferon alpha (IFN) treatment for chronic hepatitis C induces a sustained biochemical and virological response at six months after completing 24 weeks of therapy in approximately 10% of patients. The long term durability of this ‘sustained’ response is still controversial. The aim of this multicentre study was to assess the long term virological response in patients considered to have achieved a sustained biochemical response six months after completing IFN treatment. The majority (36 of 41) of the sustained responders identified had been treated for six months with IFN therapy. Twenty-nine of the 41 patients (70%) had undetectable hepatitis C virus (HCV) RNA after a mean follow-up of 38 months after cessation of treatment (range six to 92 months). All but one of those 29 individuals had normal serum alanine aminotransferase (ALT) levels. Of the 16 patients (out of 41) who had been tested for HCV RNA six months after treatment, HCV RNA remained undetectable in 14 (88%) at final follow-up. Serum ALT values in the 11 of 12 patients whose HCV RNA was positive at final follow-up were lower than pretreatment values, and in six cases were within the normal range. The long term sustained virological response in those considered a ‘sustained responder’ six months after receiving only six months of IFN is high. Measurement of ALT is an unreliable marker of sustained response to therapy.

Copyright © 2000 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.